HLA-derived peptides as novel immunomodulatory therapeutics

Barbara Murphy, Alan M. Krensky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


A growing body of experimental evidence demonstrates that synthetic peptides corresponding to linear sequences of MHC (HLA in humans) proteins have immunomodulatory effects in vitro and in vivo in animal models and in humans. Although the original concept was that these peptides inhibited antigen recognition at the MHC-T cell receptor interface via physical blockade, it is now clear that the mechanisms responsible for the myriad of functional effects are more complex. Recent findings show that some peptides affect signal transduction and cell cycle progression. Fragments of MHC molecules can dampen or downregulate immune responses via a variety of mechanisms. Some soluble MHC molecules or synthetic peptides are capable of inducing and maintaining immunologic tolerance in animals. This information suggests that synthetic peptides themselves or drugs mimicking their effects may represent a new class of immunotherapeutics.

Original languageEnglish (US)
Pages (from-to)1346-1355
Number of pages10
JournalJournal of the American Society of Nephrology
Issue number6
StatePublished - Jun 1999

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'HLA-derived peptides as novel immunomodulatory therapeutics'. Together they form a unique fingerprint.

Cite this